Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Items 901–1,000 of 1,002
Fujimura, T., Takahashi, S., Urano, T., Ijichi, N., Ikeda, K., Kumagai, J., Murata, T., Takayama, K., Horie‐Inoue, K., Ouchi, Y., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01451.x · Cited by 45
Targeting Pioneering Factor and Hormone Receptor Cooperative Pathways to Suppress Tumor Progression
Shah, S., Prasad, S., & Knudsen, K. E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-0943 · Cited by 42
“Curcumin cooperates with hormone ablation to suppress cell growth and survival in vitro Nuclear receptor–directed therapeutics typically entail agents that act through the ligand binding domain to modulate receptor signaling in disseminated prostate cancer (19, 20).”
BackgroundMethodGriend, D. J. V., Antony, L., Dalrymple, S. L., Xu, Y., Christensen, S. B., Denmeade, S. R., & Isaacs, J. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1136 · Cited by 43
“Additionally, it has been shown experimentally that if AR protein expression is elevated to a sufficient level, such that even when tissue androgen is significantly decreased after androgen ablation, a sufficient threshold of androgen/AR complexes is generated to stimulate growth signaling in the cancer cells (9).”
BackgroundYadav, S. S., Li, J., Stockert, J. A., Herzog, B. J., O'Connor, J., Garzon-Manco, L., Parsons, R. E., Tewari, A. K., & Yadav, K. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.01.011 · Cited by 43
“The development of resistance is, in part, due to the reactivation of androgen-receptor (AR) signaling [2], which prompted the development and subsequent Food and Drug Administration (FDA) approval of enzalutamide, an improved androgen-receptor antagonist, and abiraterone, a local androgen biosynthesis blocker [3,4].”
BackgroundmiR-618 Inhibits Prostate Cancer Migration and Invasion by Targeting FOXP2
Song, X., Tang, Y., Lei, X.-H., Zhao, S., & Wu, Z. (2017) · Journal of Cancer · doi:10.7150/jca.17407 · Cited by 42
“Increased AR activity is the major driver of CRCP, for example, amplification of AR gene, constitutive activation mutation and AR signaling activating by other signaling pathway [33].”
BackgroundTargeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition
Ketola, K., Munuganti, R. S. N., Davies, A., Nip, K. M., Bishop, J. L., & Zoubeidi, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0901 · Cited by 42
“Androgen deprivation therapy targeting androgen receptor (AR) and blocking its signaling is the cornerstone of therapies for prostate cancer patients withmetastatic and castration-resistant disease (2, 3).”
BackgroundRe, M. D., Crucitta, S., Sbrana, A., Rofi, E., Paolieri, F., Gianfilippo, G., Galli, L., Falcone, A., Morganti, R., Porta, C., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14792 · Cited by 44
Lorenzo, P. I., & Saatcioglu, F. (2008) · Neoplasia · doi:10.1593/neo.07985 · Cited by 44
“functional during tumor progression, suggesting an important role for AR signaling during all phases of prostate carcinogenesis [12,13].”
BackgroundWin-Piazza, H., & Acevedo-Duncan, M. E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.05.023 · Cited by 48
“to development of androgen independence in metastatic prostate cancer [1–7].”
BackgroundZhu, C., Luong, R. H., Zhuo, M., Johnson, D. T., McKenney, J. K., Cunha, G. R., & Sun, Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.269894 · Cited by 45
A role for the androgen-receptor in clinically localized and advanced prostate cancer
Mohler, J. L. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.009 · Cited by 42
“[51] Finally, preventing AR nuclear translocation or ligand binding delayed CaP recurrence in xenograft models.[51]”
BackgroundMatusik, R. J., Jin, R. J., Sun, Q., Wang, Y., Yu, X., Gupta, A., Nandana, S., Case, T. C., Paul, M., Mirosevich, J., et al. (2008) · Differentiation · doi:10.1111/j.1432-0436.2008.00276.x · Cited by 45
Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation
Frigo, D. E., & McDonnell, D. P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0480 · Cited by 42
Heitzer, M. D., & DeFranco, D. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2379 · Cited by 41
“For example, elevated AR expression may be necessary for prostate cancer progression to an androgen-independent state (55).”
BackgroundSalah, Z., Maoz, M., Pizov, G., & Bar‐Shavit, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1886 · Cited by 41
“A major drawback of hormone ablation therapy is that the reduction in tumor size is temporary: the tumor eventually proceeds to the hormone-refractory and drug-resistant stage (7).”
BackgroundProlonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
Schayowitz, A., Sabnis, G. J., Goloubeva, O. G., Njar, V. C. O., & Brodie, A. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605882 · Cited by 44
“Hypersensitivity is believed to be caused by an increase in AR expression, which is a result of AR gene amplification (Visakorpi et al, 1995; Linja et al, 2001; Edwards et al, 2003; Chen et al, 2004).”
BackgroundMostaghel, E. A., Geng, L. N., Holcomb, I. N., Coleman, I. M., Lucas, J. M., True, L. D., & Nelson, P. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2509 · Cited by 44
“Using isogenic PCa xenograft models, Chen and colleagues (38) found that a modest increase in AR was the only change consistently associated with development of resistance to antiandrogen therapy.”
MethodLeibowitz‐Amit, R., & Joshua, A. M. (2012) · Current Oncology · doi:10.3747/co.19.1281 · Cited by 44
Li, G., Wang, H., Liu, A. B., Cheung, C., Reuhl, K. R., Bosland, M. C., & Yang, C. S. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0023 · Cited by 42
“This result is consistent with the upregulation of androgen receptor commonly found in human prostate cancer (35).”
FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants
Bohrer, L. R., Liu, P., Zhong, J., Pan, Y., Angstman, J. F., Brand, L. J., Dehm, S. M., & Huang, H. (2013) · The Prostate · doi:10.1002/pros.22649 · Cited by 42
“Elevated AR protein may therefore compensate for the absence or reduced levels of androgens following hormonal therapy [4].”
BackgroundResultInfluentialKashiwagi, E., Shiota, M., Yokomizo, A., Itsumi, M., Inokuchi, J., Uchiumi, T., & Naito, S. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0344 · Cited by 43
“5B), suggesting that aspirin does not exert therapeutic effects after progression to CRPC.”
InfluentialResistance Emerges to Second-Generation Antiandrogens in Prostate Cancer
Nelson, W. G., & Yegnasubramanian, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0405 · Cited by 40
Cai, H., Memarzadeh, S., Stoyanova, T. I., Beharry, Z. M., Kraft, A. S., & Witte, O. N. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0228 · Cited by 43
“in that more than 80% of patients with castration-resistant disease maintain high androgen receptor expression or exhibit androgen receptor signaling (6, 7).”
BackgroundYao, M., Shi, X., Li, Y., Xiao, Y., Butler, W., Huang, Y., Du, L., Wu, T., Bian, X., Shi, G., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02856-5 · Cited by 41
The inhibitory effect of melatonin on human prostate cancer
Shen, D., Ju, L., Zhou, F., Yu, M., Ma, H., Zhang, Y., Liu, T., Xiao, Y., Wang, X., & Qian, K. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00723-0 · Cited by 44
Zhang, Y., & Hamburger, A. W. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602257 · Cited by 40
“Chen et al (2004) showed, using microarray-based profiling of isogenic prostate cancer xenografts, that increases in AR mRNA were the only changes consistently associated with development of resistance to antiandrogen therapy, providing a strong rationale for targeting the downregulation of…”
BackgroundProtocadherin-PC promotes androgen-independent prostate cancer cell growth
Terry, S., Queires, L. C. S., de Medina, S. G. D., Chen, M., TAILLE, A. D. L., Allory, Y., Tran, P.-L., Abbou, C. C., Buttyan, R., & Vacherot, F. (2006) · The Prostate · doi:10.1002/pros.20446 · Cited by 41
Qiu, Y., Leuschner, I., & Braun, P. M. (2008) · Asian Journal of Andrology · doi:10.1111/j.1745-7262.2008.00428.x · Cited by 41
Han, H., Qiu, L., Wang, X., Qiu, F., Wong, Y., & Yao, X. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1584 · Cited by 40
Terada, N., Shimizu, Y., Yoshida, T., Maeno, A., Kamba, T., Inoue, T., Nakamura, E., Kamoto, T., & Ogawa, O. (2009) · The Prostate · doi:10.1002/pros.21058 · Cited by 40
Imberg-Kazdan, K., Ha, S., Greenfield, A., Poultney, C. S., Bonneau, R., Logan, S. K., & Garabedian, M. J. (2013) · Genome Research · doi:10.1101/gr.144774.112 · Cited by 42
“Given such complexity, it is not surprising that AR signaling drives both early androgen-dependent as well as late castration resistant prostate cancer (CRPC) that does not respond to andro- gen deprivation therapy (Chen et al. 2004).”
BackgroundPotent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent
Purushottamachar, P., Khandelwal, A., Vasaitis, T. S., Bruno, R. D., Gediya, L. K., & Njar, V. C. O. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.02.031 · Cited by 46
Asim, M., Hafeez, B. B., Siddiqui, I. A., Gerlach, C., Patz, M., Mukhtar, H., & Baniahmad, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.292771 · Cited by 47
The role of microRNA in castration-resistant prostate cancer
Thieu, W., Tilki, D., White, R. D., & Evans, C. P. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.11.004 · Cited by 41
“As AR up-regulation has been implicated in the conversion of prostate cancer to CRPC, miR-let-7c may be involved in this potential pathway [6].”
BackgroundEnzalutamide: Development from bench to bedside
Bambury, R. M., & Scher, H. I. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.12.017 · Cited by 41
“The effort to develop such a compound began with an experiment whereby a series of 7 matched pre-ADT castration-sensitive and post-ADT castration-resistant prostate cancer cell lines were profiled to identify differences in gene expression [20].”
BackgroundSpatial interactions and cooperation can change the speed of evolution of complex phenotypes
Komarova, N. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400828111 · Cited by 39
Regulation of Androgen Receptor-Mediated Transcription by RPB5 Binding Protein URI/RMP
Mita, P., Savas, J. N., Djouder, N., Yates, J. R., Ha, S., Ruoff, R., Schafler, E. D., Nwachukwu, J. C., Tanese, N., Cowan, N. J., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05429-11 · Cited by 39
“Widespread interest in the mechanism of transcriptional regulation by the androgen receptor (AR) has been stimulated by the finding that AR signaling is critically important in the progression of both androgen-dependent and castration-resistant prostate cancers (2, 9).”
BackgroundNovel, Potent Anti-Androgens of Therapeutic Potential: Recent Advances and Promising Developments
Vasaitis, T. S., & Njar, V. C. O. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.14 · Cited by 41
Rajan, P., Dalgliesh, C., Carling, P. J., Buist, T. J., Zhang, C., Grellscheid, S. N., Armstrong, K., Stockley, J., Simillion, C., Gaughan, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029088 · Cited by 43
“progression of prostate cancer (PCa) [1], the second leading cause of male cancer-related deaths with ,899,000 men diagnosed”
BackgroundEpigenetic therapy in urologic cancers: an update on clinical trials
Faleiro, I., Leao, R. R. N., Binnie, A., de Mello, R. A., Maia, A.-T., & Castelo‐Branco, P. (2016) · Oncotarget · doi:10.18632/oncotarget.14226 · Cited by 46
“com/oncotarget Downstream activation of the androgen receptor pathway and activation of an alternative signaling pathway can also contribute to hormonal therapy resistance [46].”
BackgroundDasari, S., Samy, A. L. P. A., Kajdacsy‐Balla, A., Bosland, M. C., & Munirathinam, G. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.02.018 · Cited by 43
“• VK2 down regulates androgen receptor, Oct3/4 (stem cell marker) and key anti-apoptotic genes to target CRPC. • VK2 is a potential anti-cancer agent for CRPC treatment.”
BackgroundInfluentialThe potential of AR-V7 as a therapeutic target
Uo, T., Plymate, S. R., & Sprenger, C. C. T. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1439016 · Cited by 41
“At this stage, the patient is considered depleted of androgen and thus the PCa presumably grew independently of AR signaling [6,7].”
BackgroundCarcinogenesis in prostate cancer: The role of long non-coding RNAs
Aird, J. J., Baird, A., Lim, M. C. J., McDermott, R., Finn, S. P., & Gray, S. G. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.01.001 · Cited by 42
der Eecken, K. V., Vanwelkenhuyzen, J. P., Deek, M. P., Tran, P. T., Warner, E. W., Wyatt, A. W., Kwan, E. M., Verbeke, S., Dorpe, J. V., Fonteyne, V., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.10.005 · Cited by 44
“AR aberrations were exclusively identified in tumour samples that were collected following ADT exposure, consistent with the known role of the transition towards castration-resistant disease [19].”
Clark, E. L., Hadjimichael, C., Temperley, R., Barnard, A., Fuller-Pace, F. V., & Robson, C. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054150 · Cited by 45
“Aberrant activation of the AR is thought to play a prominent role in the development of CRPCa; a process postulated to be, in part, mediated via uncontrolled activation of co-activator proteins that facilitate the expression of AR responsive genes in a minimal hormone environment [3].”
BackgroundZhang, Y., Kim, K., Zhang, W., Guo, Y., Kim, S., & Lü, J. (2011) · International Journal of Cancer · doi:10.1002/ijc.25993 · Cited by 42
“37,38 These observations support that AR still plays a crucial role for the progression of CRPCa.”
BackgroundInfluentialCholesterol as a Potential Target for Castration-Resistant Prostate Cancer
Twiddy, A. L., Leon, C. G., & Wasan, K. M. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0210-y · Cited by 43
Bettoun, D. J., Scafonas, A., Rutledge, S. J., Hodor, P. G., Chen, O., Gambone, C. J., Vogel, R., McElwee-Witmer, S., Bai, C., Freedman, L. P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500324200 · Cited by 39
Andrographolide Targets Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
Liu, C., Nadiminty, N., Tummala, R., Chun, J. Y., Lou, W., Zhu, Y., Sun, M., Evans, C. P., Zhou, Q., & Gao, A. C. (2011) · Genes & Cancer · doi:10.1177/1947601911409744 · Cited by 42
Sato, M., Johnson, M., Zhang, L., Gambhir, S. S., Carey, M., & Wu, L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1990 · Cited by 39
Johnson, M., Sato, M., Burton, J., Gambhir, S. S., Carey, M., & Wu, L. (2005) · Molecular Imaging · doi:10.2310/7290.2005.05154 · Cited by 39
“In this tumor model, serum PSA measurements have been shown to accurately reflect tumor volume and growth in several studies [29,31–33].”
Phosphorylation and activation of androgen receptor by Aurora-A.
Shu, S.-K., Liu, Q., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121129 · Cited by 38
RetractedMicroRNAs as putative mediators of treatment response in prostate cancer
O’Kelly, F., Marignol, L. H., Meunier, A., Lynch, T. H., Perry, A. S., & Hollywood, D. P. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.104 · Cited by 41
Role of Androgen Receptor in Progression of LNCaP Prostate Cancer Cells from G1 to S Phase
Murthy, S., Wu, M., Bai, V. U., Hou, Z., Menon, M., Barrack, E. R., Kim, S., & Reddy, G. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056692 · Cited by 38
Shabbir, M., Syed, D. N., Lall, R. K., Khan, M. R., & Mukhtar, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119859 · Cited by 38
RetractedSu, S., Minges, J. T., Grossman, G., Blackwelder, A. J., Mohler, J. L., & Wilson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.468579 · Cited by 40
“Increased AR expression may be a molecular basis for prostate cancer progression (113).”
BackgroundChinnakannu, K., Chen, D., Li, Y., Wang, Z. P., Dou, Q. P., Reddy, G. P. V., & Sarkar, F. H. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21650 · Cited by 38
“L I S S , I N C . play important roles in development of prostate cancer and progression of androgen-sensitive tumors to hormonerefractory state (Chen and Sawyers, 2002; Chen et al., 2004).”
BackgroundDing, G., Feng, C., Jiang, H., Ding, Q., Zhang, L., Na, R., Xu, H., & Liu, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077400 · Cited by 38
“Among its client proteins are transcription factors, cell cycle regulators, signaling kinases, doi: 10.1371/journal.pone.0077400.g005 PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e77400 mediators of apoptosis as well as steroid hormone receptors, such as the androgen receptor (AR), which have crit…”
BackgroundInfluentialSarwar, M., Sandberg, S., Abrahamsson, P., & Persson, J. L. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.08.019 · Cited by 45
“[26] have shown that increase in AR mRNA is sufficient for the conversion of the phenotype of CaP from androgen-dependent to androgenindependent in a xenograft model.”
BackgroundCui, Y., Nadiminty, N., Liu, C., Lou, W., Schwartz, C. T., & Gao, A. C. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0107 · Cited by 41
“…cause of cancer-related death among men in the United States, prostate tumors respond to androgen deprivation therapy initially; however, after time, relapse occurs and develops into a lethal form of disease, termed castration-resistance prostate cancer (CRPC; Chen et al. 2004, Harris et al. 2009).”
Therapy assessment in prostate cancer using choline and PSMA PET/CT
Ceci, F., Herrmann, K., Hadaschik, B. A., Castellucci, P., & Fanti, S. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3723-3 · Cited by 38
Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression
Takayama, K., Misawa, A., & Inoue, S. (2017) · Cancers · doi:10.3390/cancers9080102 · Cited by 40
Interference with the androgen receptor protein stability in therapy‐resistant prostate cancer
Lakshmana, G., & Baniahmad, A. (2018) · International Journal of Cancer · doi:10.1002/ijc.31818 · Cited by 40
Larsson, P., Khaja, A. S. S., Semenas, J., Wang, T., Sarwar, M., Dizeyi, N., Simoulis, A., Hedblom, A., Wai, S. N., Ødum, N., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32607 · Cited by 42
Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy
Sha, J., Han, Q., Chi, C., Zhu, Y., Pan, J., Dong, B., Huang, Y., Xia, W., & Xue, W. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29117 · Cited by 40
“The pathogenesis of CRPC is predominantly promoted by highly activated androgen receptor signaling and the coactivators or mediators in AR signaling are usually considered as the effective therapeutic targets to cure CRPC (Asangani et al., 2014; Attard, Richards, & de Bono, 2011; Chen et al., 2004; Taylor et al., 2010…”
BackgroundDynamics of Cellular Plasticity in Prostate Cancer Progression
Tiwari, R., Manzar, N., & Ateeq, B. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00130 · Cited by 42
Tang, Y., & Cao, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030422 · Cited by 45
TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2/CCR2 signaling
Ding, X., Yang, D., Lee, S. O., Chen, Y., Xia, L., Lin, S.-J., Yu, S., Niu, Y., Li, G., & Chang, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.29049 · Cited by 38
Tamburrino, L., Salvianti, F., Marchiani, S., Pinzani, P., Nesi, G., Serni, S., Forti, G., & Baldi, E. (2012) · Steroids · doi:10.1016/j.steroids.2012.01.008 · Cited by 41
“The increase in AR gene and protein expression was modest, but AR acquired the ability to respond to anti-androgens and to aberrantly recruit coactivators to the promoters [3].”
Background20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer
Cao, B., Qi, Y., Yang, Y., Liu, X., Xu, D., Guo, W., Zhan, Y., Xiong, Z., Zhang, A., Wang, A. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111201 · Cited by 38
“Overexpression of AR-FL was shown to sensitize the receptor to low levels of androgen [25] and to convert prostate cancer growth from a castration-sensitive to a castration-resistant stage [10].”
BackgroundTakahara, K., Azuma, H., Sakamoto, T., Kiyama, S., Inamoto, T., Ibuki, N., Nishida, T., Nomi, H., Ubai, T., Segawa, N., et al. (2009) · PubMed · Cited by 45
Androgen Deprivation Therapy as Primary Treatment for Prostate Cancer
Cannata, D., Kirschenbaum, A. M., & Levine, A. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2353 · Cited by 37
Influence of stromal–epithelial interactions on androgen action
Nieto, C., Rider, L. C., & Cramer, S. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0138 · Cited by 40
“The AR itself adapts to the sudden lack of androgens by increasing the number of receptors in the cell so that any available androgens are readily bound or by becoming hypersensitive to ligands that may be scarce (Chen et al. 2004, Taplin 2008).”
BackgroundMisawa, A., Takayama, K., Fujimura, T., Homma, Y., Suzuki, Y., & Inoue, S. (2016) · Cancer Science · doi:10.1111/cas.13151 · Cited by 37
Kita, Y., Goto, T., Akamatsu, S., Yamasaki, T., Inoue, T., Ogawa, O., & Kobayashi, T. (2018) · Cancers · doi:10.3390/cancers10100345 · Cited by 41
“A substantial proportion of patients with low-risk PC achieve durable responses with almost complete remission by ADT alone, which lowers the benefit of combined treatment.”
BackgroundInfluentialLuo, J., Li, Y., Zheng, W., Xie, N., Shi, Y., Long, Z., Xie, L., Fazli, L., Zhang, D., Gleave, M. E., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.015 · Cited by 43
Jiang, B., Mu, Q., Qiu, F., Li, X., Xu, W., Yu, J., Fu, W., Cao, Y. B., & Wang, J. (2021) · Nature Communications · doi:10.1038/s41467-021-27017-w · Cited by 43
“And Kaplan – Meier plot (KM plot) is used to illustrate survival differences among different strati fi ed groups. depletion therapy 23,24 .”
MethodMitsiades, N., & Kaochar, S. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0098 · Cited by 41
Bonaccorsi, L., Nosi, D., Quercioli, F., Formigli, L., Zecchi, S., Maggi, M., FORTI, G., & Baldi, E. (2008) · Steroids · doi:10.1016/j.steroids.2008.01.028 · Cited by 41
Zhou, W., Gui, M., Zhu, M., Long, Z., Huang, L., Zhou, J., He, L., & Zhong, K. (2014) · Oncology Letters · doi:10.3892/ol.2014.2287 · Cited by 37
“However, the majority of these patients progress to hormone independence, the predominant obstacle that currently stops improvements in patient survival and quality of life (4,5).”
BackgroundXiao, D., & Singh, S. V. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0079-9 · Cited by 42
The Interplay of AMP-Activated Protein Kinase and Androgen Receptor in Prostate Cancer Cells
Shen, M., Zhang, Z., Ratnam, M., & Dou, Q. P. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24494 · Cited by 39
Yamamoto, S., Takayama, K., Obinata, D., Fujiwara, K., Ashikari, D., Takahashi, S., & Inoue, S. (2019) · Cancer Science · doi:10.1111/cas.14183 · Cited by 37
Whitaker, H. C., Hanrahan, S., Totty, N., Gamble, S. C., Waxman, J., Cato, A. C. B., Hurst, H. C., & Bevan, C. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0388 · Cited by 37
“In around 30% of advanced prostate cancers, AR levels appear to be amplified (39), which may result in AR antagonists acting as weak agonists (42).”
BackgroundAgoulnik, I. U., Bingman, W. E., Nakka, M., Li, W., Wang, Q., Liu, X. S., Brown, M., & Nancy L., N. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0481 · Cited by 36
“In comparisons of androgendependent tumors with androgen-independent tumors from humans and from xenografts, the most consistent difference is an elevation in AR expression in the androgen ablation-resistant tumors (2).”
Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells
Liu, T., Fang, Z., Wang, G., Shi, M., Wang, X., Jiang, K., Yang, Z., Cao, R., Tao, H., Wang, X., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.3854 · Cited by 36
“However, in later stages, PCa is more invasive and evolves to become androgen-independent, with a resistance to not only androgen-ablative therapy, but also to various other chemotherapy regimens (5-9).”
Vinall, R. L., Hwa, K., Ghosh, P., Pan, C.-X., Lara, P. N., & White, R. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0600 · Cited by 36
Smith, A. M., Findlay, V. J., Bandurraga, S. G., Kistner‐Griffin, E., Spruill, L., Liu, A., Golshayan, A., & Turner, D. P. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs007 · Cited by 38
Li, L., Xie, H., Liang, L., Gao, Y., Zhang, D., Fang, L., Lee, S. O., Luo, J., Chen, X., Wang, X., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs337 · Cited by 37
“Interestingly, immunohistochemical analyses have shown that most tumors at this castration-resistant stage continue to express the androgen receptor (AR) and the AR target gene prostate-specific antigen (PSA), suggesting that the AR signals may be still functional, regardless of ADT treatment (4,5).”
BackgroundRanasinghe, W. K. B., Sengupta, S., Williams, S., Chang, M., Shulkes, A., Bolton, D. M., Baldwin, G., & Patel, O. (2014) · Cancer Medicine · doi:10.1002/cam4.189 · Cited by 36
“Expression of androgen receptors has been linked with development of castrate resistance [8], and shown to be upregulated by HIF1a [9].”
BackgroundShamaladevi, N., Lyn, D. A., Shaaban, K. A., Zhang, L., Villate, S., Rohr, J., & Lokeshwar, B. L. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt123 · Cited by 39
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
Wadosky, K. M., & Koochekpour, S. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14090 · Cited by 44
“this context, the AR inhibitory activity of 200 derivatives of RU59063, an AR super-agonist, was assessed specifically in the presence of increased AR expression (a setting that approximates the CR-PCa disease state since AR protein levels are elevated in recurrent tumors and cell lines) [117-119].”
BackgroundTakayama, K., Suzuki, T., Fujimura, T., Takahashi, S., & Inoue, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721957115 · Cited by 43
“Enhanced AR signaling in CRPC has been observed in several studies (7, 8).”
BackgroundGao, B., Lue, H.-W., Podolak, J., Fan, S., Zhang, Y., Serawat, A., Alumkal, J. J., Fiehn, O., & THOMAS, G. V. (2019) · Metabolites · doi:10.3390/metabo9050082 · Cited by 38
“Androgen receptor signaling is the primary driver of prostate cancer, and subsequently, medical castration with androgen deprivation therapy is the backbone of all treatments in men with metastatic prostate cancer [1,2].”
BackgroundACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Kim, E. H., Cao, D., Mahajan, N. P., Andriole, G. L., & Mahajan, K. N. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa018 · Cited by 40
“However, patients invariably develop resistance to ADT and progress to a lethal stage referred to as CRPC (11,13).”
BackgroundResistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
Verma, S., Prajapati, K. S., Kushwaha, P. P., Shuaib, M., Singh, A. K., Kumar, S., & Gupta, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.45 · Cited by 48
“Several reports suggest that both AR responsive or refractory prostate cancer harbor increased AR expression due to genetic amplification of AR genes and AR enhancer elements([11-14]).”
BackgroundAndrogen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids
Snaterse, G., Mies, R., van Weerden, W. M., French, P. J., Jonker, J. W., Houtsmuller, A. B., van Royen, M. E., Visser, J. A., & Hofland, J. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00491-z · Cited by 41
Zhao, H., Flamand, V., & Peehl, D. M. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-55 · Cited by 37
“In PCa xenografts, an increase in AR mRNA and protein was both necessary and sufficient to convert growth from a hormone-sensitive to a hormonerefractory stage [37], while knocking down AR reduced cell growth in both androgen-sensitive and -insensitive cancer cells [46].”
BackgroundResultMetastatic Castration-Resistant Prostate Cancer: Time for Innovation
Tucci, M., Scagliotti, G. V., & Vignani, F. (2015) · Future Oncology · doi:10.2217/fon.14.145 · Cited by 39
Hoffmann, J., & Sommer, A. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.12.002 · Cited by 46
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.